Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform in the United States, Germany, and internationally. Its flagship product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses, bilirubin in liver failure, myoglobin in trauma and critical illnesses, and inflammatory mediators and blood thinners in cardiac surgery applications, as well as to remove antithrombotic drugs and inflammatory mediators in cardiothoracic surgery applications. The company also develops DrugSorb-ATR antithrombotic removal system, an investigational device to reduce the severity of perioperative bleeding in high-risk surgery due to blood thinning drugs; ECOS-300CY to reduce cytokines and other inflammatory mediators when used in an ex vivo organ perfusion system; VetResQ, a broad-spectrum blood purification adsorber for the treatment of septic shock, toxic shock syndrome, toxin-mediated diseases, pancreatitis, trauma, liver failure, heat stroke, and lung injury in animals; and PuriFi, an advanced hemoperfusion pump for blood purification therapies. In addition, it develops HemoDefend-BGA, a blood purification technology platform to reduce anti-A and anti-B antibodies in plasma and whole blood. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.…
CTSO: CytoSorbents Reaches Positive Operating Cash Flow in the 3rd Quarter
CytoSorbents to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Cytosorbents (NASDAQ: CTSO) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 129 employees.
The shares were at 4.160 USD on 20 November 2026, down 70.6% over 52 weeks. Its 52-week range is 2.840 USD to 17.00 USD: the price is 75.5% below the high and 46.5% above the low.
Its market capitalisation is 13.11M USD.
Cytosorbents reports return on equity of -138.9%, an operating margin of -27.7% and revenue up 2.6% year over year.
Its debt exceeds its cash by 25.37M USD, a debt-to-equity ratio of 4.93. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. The next earnings report is expected on 24 March 2027.